Репозиторий Университета

© 2018 Dynasty Publishing House. All rights reserved. The objective. To perform a budget impact analysis of a novel antiretroviral drug elsulfavirine (ESV) compared with currently used medical technologies. Materials and methods. The pharmacoeconomic model was based on the studies of efficacy and safety of two non-nucleoside reverse transcriptase inhibitors: ESV and rilpivirine (RPV) combined with standard basic tenofovir/ emtricitabine (TDF/FTC) therapy for 48 weeks. The studies were performed in similar clinical settings. The budget impact analysis assessed only direct medical costs of antiretroviral drugs within the chosen strategies of first-line antiretroviral therapy (ART). Results. It was shown that the treatment of ART-naive HIV patients with ESV is associated with 61,234.88 RUB less costs per patient in a 48-week course compared with RPV treatment. The analyzed values of cost effectiveness were lower for ESV strategy than for the strategy with the use of RPV. It makes ESV a more cost-efficient option within the developed model. Conclusion. The use of ESV is a preferable strategy of a first-line treatment of HIV. It is associated with less financial costs and more preferable cost effectiveness rate.